Cognition Therapeutics, Inc.
CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer'sā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.98
Price-0.32%
$0.00
1Y
Price
Market Cap
$87.601m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$19.577m
+16.7%
1y CAGR+5.3%
3y CAGR-872.7%
5y CAGREPS
-$0.26
+18.8%
1y CAGR+27.4%
3y CAGR+16.5%
5y CAGRBook Value
$29.911m
$36.140m
Assets$6.229m
Liabilities$465k
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$20.253m
+17.6%
1y CAGR-15.0%
3y CAGR-7.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company